How to Test for Endometriosis: Your Complete Guide to Diagnosis

Endometriosis is a condition in which tissue similar to the uterine lining (endometrium) grows outside the uterus, most often on the ovaries, the peritoneum lining the pelvis, the bowel, or the bladder. It is not the same condition as adenomyosis, in which that tissue grows into the muscular wall of the uterus itself, though the two can occur together. This article covers how clinicians actually investigate suspected endometriosis and where the real diagnostic uncertainty lies.

The direct answer

No blood test, and no imaging study on its own, can definitively confirm or rule out endometriosis. Transvaginal ultrasound and pelvic MRI can identify ovarian endometriomas and, in experienced hands, deep infiltrating disease with reasonably good accuracy, but the diagnostic gold standard remains surgical laparoscopy with histological biopsy showing endometrial glands and stroma outside the uterus. Because laparoscopy carries surgical risk and cost, many clinicians and guidelines, including the European Society of Human Reproduction and Embryology (ESHRE) 2022 guideline, now support building a working diagnosis from symptoms plus imaging and reserving surgery for cases that need definitive staging, a tissue diagnosis, or treatment of visible disease (Becker et al., 2022).

The practical question for most patients is not "which single test proves I have endometriosis," but "how much diagnostic certainty do I need before I accept the tradeoffs of surgery." That tradeoff is the organizing idea behind the decision framework further down this page.

Why diagnosis so often takes years

Multiple studies across different health systems have documented long gaps between symptom onset and confirmed diagnosis. A multicenter survey across ten countries found that a majority of women with endometriosis saw a physician multiple times before being referred to a specialist (Nnoaham et al., 2011). A separate study of diagnostic delay in Austria and Germany examined the causes behind these gaps, including symptom normalization by both patients and clinicians and inconsistent use of specialist referral pathways (Hudelist et al., 2012). Exact average delay figures vary by country and study design, so treat any single "7 to 10 years" number as a general pattern reported in the literature rather than a fixed statistic that applies to every patient.

Part of the delay is biological. Endometrial-like implants bleed and inflame surrounding tissue with each menstrual cycle, but because the pelvis has no external outlet for that bleeding, damage accumulates slowly and symptoms often intensify gradually rather than announcing themselves as an acute problem.

Conditions that can look like endometriosis

Pain pattern alone cannot confirm the diagnosis. Irritable bowel syndrome, interstitial cystitis, pelvic inflammatory disease, ovarian cysts, and adenomyosis can all produce similar pelvic pain, painful periods, or pain with intercourse. Endometriosis is commonly misdiagnosed as irritable bowel syndrome before a gynecologic cause is identified, though the exact rate of this misdiagnosis varies across studies and is not something this article can pin to a single number. Adenomyosis frequently coexists with endometriosis, though published co-occurrence estimates vary depending on imaging method and study population; a systematic review of adenomyosis and IVF outcomes touches on this overlap as background but was not designed to establish a precise co-occurrence rate (Vercellini et al., 2014).

Before any endometriosis-specific workup, clinicians typically rule out pregnancy and infection, since both change the diagnostic and treatment path entirely.

Step 1: Symptom history and pain tracking

Diagnosis starts with a structured history, not a blood draw. Three symptoms together are what typically raise clinical suspicion enough to justify imaging:

1. Dysmenorrhea (painful periods) severe enough to limit daily activity or require prescription-strength pain relief.
2. Dyspareunia (pain during or after intercourse), particularly deep pain that worsens around menstruation.
3. Chronic pelvic pain lasting six months or longer, present outside of menstruation as well.

Cyclical bowel symptoms, cyclical urinary symptoms, and unexplained infertility are additional flags. Professional guidance from the American College of Obstetricians and Gynecologists has, in past practice guidance, framed endometriosis as a diagnosis to actively consider in women of reproductive age presenting with pelvic pain, dysmenorrhea, dyspareunia, or infertility, rather than a diagnosis of exclusion reached only after everything else is ruled out (ACOG Practice Bulletin, 2010, reaffirmed 2018). Because this bulletin has since been updated in ACOG's guidance library, confirm the current version with a clinician rather than relying on the exact wording here.

Tracking pain scores across two or three full menstrual cycles gives a clinician far more to work with than a single recalled description. Mobile symptom-tracking apps have been compared against paper diaries for capturing cycle-related symptoms, with reasonable agreement reported in at least one validation study, though the strength of that agreement depends on which symptoms and which app are being compared (Symul et al., 2019).

Step 2: The pelvic exam, and what it can't tell you

A physical pelvic exam cannot confirm endometriosis. It can raise or lower suspicion. Clinicians examine for a fixed, retroverted uterus, tenderness, and nodularity along the uterosacral ligaments on rectovaginal exam, findings associated with more advanced or deep disease. A speculum exam occasionally reveals visible lesions on the cervix or vaginal wall, though this is uncommon.

Exam sensitivity is limited, particularly for superficial peritoneal disease, which is common in earlier-stage endometriosis and rarely produces a palpable finding. Studies of diagnostic delay have examined how inconsistent physical exam practices contribute to missed or delayed diagnosis, but this article does not have a source that supports a precise sensitivity percentage for exam alone, so no specific number is presented here. If your exam is normal, that does not rule out endometriosis.

Step 3: Imaging, and why the type of scan matters

A standard transabdominal ultrasound is inadequate for most endometriosis patterns. The scan ordered matters more than most patients realize.

Transvaginal ultrasound (first-line)

Transvaginal ultrasound performed by a sonographer experienced with endometriosis is the first-line imaging test recommended by the ESHRE 2022 guideline (Becker et al., 2022). It is good at detecting ovarian endometriomas, which have a characteristic appearance, and specialized protocols can also assess for deep disease in the rectovaginal area. A systematic review and meta-analysis of transvaginal ultrasound for deep endometriosis in the rectosigmoid region reported high sensitivity and specificity for that specific finding when performed by experienced examiners (Guerriero et al., 2016); results in general practice, with less specialized operators, are likely to be lower.

MRI

Pelvic MRI with a dedicated protocol is generally used for mapping deep infiltrating disease before surgery, because it can help identify bowel, bladder, or ureteral involvement that changes the surgical plan and the specialist team required. Reported sensitivity and specificity figures for MRI in endometriosis vary across studies; one frequently cited pooled estimate in the literature that this article originally relied on was actually drawn from a study of adenomyosis imaging rather than endometriosis specifically (Bazot and Darai, 2018), so treat any single sensitivity or specificity percentage for MRI in endometriosis as needing confirmation against an endometriosis-specific study rather than a settled fact.

Standard ultrasound is usually not enough

A regular transabdominal ultrasound reliably picks up only larger endometriomas. It routinely misses peritoneal implants and early-stage disease. If you are told your ultrasound was "normal" and it was not a dedicated transvaginal endometriosis protocol, ask whether a repeat scan with the right technique is warranted.

Step 4: Blood tests, and why none stand alone

No blood test can confirm or rule out endometriosis with the reliability needed for a clinical decision.

CA-125 is the most commonly ordered marker. In endometriosis, it has been reported to have roughly 50% sensitivity for earlier-stage disease, with higher sensitivity at more advanced stages, based on an older but still frequently cited meta-analysis (Mol et al., 1998). CA-125 also rises with fibroids, pelvic infection, early pregnancy, and ovarian cancer, which is why it is not recommended as a standalone screening test.

Emerging biomarkers are under active research but are not yet clinically validated replacements for laparoscopy or imaging:

• A serum microRNA panel showed promising discrimination in a discovery cohort, but this kind of finding needs independent validation before clinical use (Cosar et al., 2016).
• Neutrophil-to-lymphocyte ratio has been proposed as a low-cost inflammatory marker, but its predictive value on its own is modest and it is not endorsed by major guidelines as a diagnostic test (Kwak et al., 2022).

As of this writing, no blood or urine biomarker panel has FDA clearance specifically for diagnosing endometriosis. Regulatory status can change, so confirm current status if this matters to a specific decision.

Step 5: Laparoscopy, the diagnostic gold standard

Laparoscopy is minimally invasive surgery, performed under general anesthesia, in which a camera is inserted through small abdominal incisions to directly view the pelvic organs. A tissue diagnosis requires biopsy showing endometrial glands and stroma outside the uterus; visual inspection alone, without biopsy, can be wrong, especially for lesions that don't look like the classic dark "powder-burn" spots. Atypical-appearing lesions, such as clear vesicles or white plaques, are known to be under-recognized by surgeons without endometriosis-specific training. This article's underlying source list does not include a study that directly quantifies how often atypical lesions are missed, so any specific percentage on that point should be verified rather than repeated as settled.

Most gynecologic surgeons treat visible lesions at the same procedure as diagnosis, to avoid a second anesthetic exposure, which is consistent with current ESHRE surgical guidance (Becker et al., 2022).

ASRM staging (rASRM)

The American Society for Reproductive Medicine's revised staging system assigns points at laparoscopy based on lesion size, location, depth, and adhesion severity:

• Stage I (Minimal): 1 to 5 points, superficial implants
• Stage II (Mild): 6 to 15 points
• Stage III (Moderate): 16 to 40 points, deeper implants, endometriomas, adhesions
• Stage IV (Severe): more than 40 points, extensive disease and dense adhesions

Confirm exact thresholds against current ASRM documentation, since classification systems are periodically revised. More importantly for patients: stage does not reliably predict pain severity. A study following surgically treated patients found that the classification system had limited predictive value for pain recurrence and reproductive outcomes (Vercellini et al., 2006). Some people with minimal-stage disease have debilitating pain; some with severe-stage disease have mild symptoms.

Beyond rASRM: the Enzian classification

The Enzian system specifically scores deep infiltrating disease by anatomical compartment (rectovaginal, parametrial, bowel, bladder, ureter) and is increasingly used in specialist surgical centers to standardize reporting of deep disease, as described in surgical treatment recommendations for deep endometriosis (Keckstein et al., 2020).

The empirical hormonal trial: a middle path, not a diagnosis

In patients with a classic symptom pattern and no clear findings on imaging, some clinicians offer a trial of hormonal therapy, such as a combined oral contraceptive or a progestin, before considering laparoscopy. The ESHRE 2022 guideline supports offering empirical hormonal treatment as an alternative to surgical diagnosis in appropriately selected patients, provided other causes of pelvic pain have been reasonably excluded (Becker et al., 2022).

Pain improvement on this trial is supportive, not confirmatory, because hormonal suppression also relieves pain from other causes of dysmenorrhea. It avoids surgical risk but delays a tissue diagnosis and formal staging. For someone actively trying to conceive soon, this tradeoff matters: hormonal suppression is not compatible with attempting pregnancy, so the empirical-trial path and the fertility-focused path pull in different directions.

What excision versus ablation means for recurrence

When lesions are treated at laparoscopy, surgeons either excise (cut out) or ablate (burn the surface of) the tissue. A Cochrane review of laparoscopic surgery for endometriosis examined outcomes for these approaches and found evidence favoring excision for reducing symptom recurrence, particularly for deeper disease, though the exact magnitude reported depends on which outcome and follow-up period is examined (Duffy et al., 2014). This is a reasonable question to raise directly with a surgeon before a planned procedure.

A decision framework: what should actually happen next

Your best next step depends on how severe your symptoms are, your timeline for pregnancy, what imaging may have already revealed, and your comfort level with surgical risk. Below, we've organized common scenarios with reasonable options and their rationale to help guide your discussion with a doctor, though this guide cannot replace personalized medical advice.

Building your case before an appointment

Bring two to three months of pain-tracking data, a list of pain medications tried and whether they helped, and any family history of endometriosis in a first-degree relative, which is a recognized (though not precisely quantified in the sources behind this page) risk factor worth mentioning. If symptoms have persisted more than six months without an explanation, it is reasonable to ask for a referral to a gynecologist with specific experience in endometriosis rather than continuing with a general provider alone.

Useful questions to ask:

• "Are you ordering a transvaginal or transabdominal ultrasound? I understand transvaginal is more sensitive for this."
• "Does the imaging center use a dedicated endometriosis protocol?"
• "If laparoscopy is recommended, would you excise or ablate lesions, and why?"

What is established, what is plausible, and what isn't

Established: Laparoscopy with histological biopsy is the accepted diagnostic gold standard. CA-125 alone is not an adequate screening test. Transvaginal ultrasound is the recommended first-line imaging test, and standard transabdominal ultrasound is inadequate for most disease patterns. Symptom pattern and stage do not reliably correlate with each other.

Plausible but not settled: Emerging blood biomarkers such as microRNA panels may eventually support earlier or non-surgical diagnosis, but they have not been independently validated for clinical use. Empirical hormonal trials appear to help select patients avoid unnecessary surgery, but this has not been shown to be equivalent to a tissue diagnosis for staging purposes.

Not established, or not something this page can confirm precisely: Exact percentages for physical exam sensitivity, the exact rate at which endometriosis is initially misdiagnosed as IBS, and a single precise family-history risk multiplier are all cited inconsistently across sources. Where this article could not verify a specific number against a source that actually measured it, it has said so rather than presenting a number as settled fact.